Cord Blood News 12.13 April 9, 2020 | |
| |
TOP STORYResearchers report the outcomes of 129 patients with Wiskott-Aldrich syndrome who underwent hematopoietic cell transplantation at 29 Primary Immune Deficiency Treatment Consortium centers between 2005 and 2015. With a median follow-up of 4.5 years, the 5-year overall survival (OS) was 91%. OS was excellent regardless of donor type even in cord blood recipients. [Blood] Abstract | |
| |
PUBLICATIONS(Ranked by impact factor of the journal)Pluronic F-127 (PF-127) was found to be cytotoxic to Wharton’s jelly MSCs (WJMSCs) while sodium ascorbyl phosphate significantly improved the survival of PF-127-embedded WJMSCs. [Stem Cell Res Ther] Full Article Scientists investigated the gene expression profile via single-cell RNA sequencing of human primary Wharton’s jelly-derived MSCs cultured in vitro from three donors. [Stem Cell Res Ther] Full Article Human telomerase-immortalized corneal epithelial cells were characterized and its functions evaluated by scratch migration assay, cellular senescence, HLA expression and spheres formation with human umbilical cord-derived MSCs. [Regen Med] Abstract From Cord to Eye: Wharton Jelly-Derived Stem Cells Differentiate Into Corneal Endothelial-Like Cells A well-characterized, functional corneal endothelial cell monolayer was developed by using a Descemet-like topography-mediated mechanotransductive differentiation of Wharton jelly-derived MSCs. [Cornea] Abstract MSCs were generated from umbilical cord blood. Hepatogenic differentiation was induced on 2D and 3D culture system and characterized by morphology, scanning electron microscopy, immunocytochemistry, and gene expression. [Cell Reprogram] Abstract Subscribe to one of our other 19 science newsletters such as Hematopoiesis News & Cell Therapy News. | |
| |
REVIEWSTreatment and Unmet Needs in Steroid-Refractory Acute Graft-versus-Host Disease The authors review current treatment options for patients with steroid-refractory acute graft-versus-host disease and discuss data from recently published clinical studies to outline emerging therapeutic strategies. [Leukemia] Abstract Visit our reviews page to see a complete list of reviews in the cord blood research field. | |
| |
INDUSTRY NEWSCellect Biotechnology Receives New Patent Allowance in China Cellect Biotechnology Ltd. received an official communication from the China National Intellectual Property Administration regarding its intention to grant Chinese Patent Application No. 201380021092.5. [Cellect Biotechnology Ltd. (PR Newswire Association LLC)] Press Release Pfizer Receives European Approval for Oncology Biosimilar, RUXIENCE™ (Rituximab) Pfizer Inc. announced that the European Commission has approved RUXIENCE™, a monoclonal antibody and biosimilar to MabThera®, for the treatment of non-Hodgkin’s lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, granulomatosis with polyangiitis and microscopic polyangiitis, and pemphigus vulgaris. [Pfizer Inc.] Press Release | |
| |
POLICY NEWSEarly-Career Scientists at Critical Career Junctures Brace for Impact of COVID-19 For some scientists, the shutdowns have made it more challenging for them to complete their work. But for others, they come at a critical juncture in the scientist’s career, threatening to derail or delay a major event along their professional path—a small slice of the human suffering and inconvenience that COVID-19 has caused. [ScienceInsider] Editorial President of Europe’s Premier Science Funder Resigns amid Criticism that He Neglected Post The president of Europe’s most prestigious funding agency has resigned suddenly after only three months in the post – prompting fiery accusations from the organization’s governing body that he largely neglected his responsibilities. [Nature News] Editorial
| |
EVENTSIn light of COVID-19, many conferences are being cancelled or postponed. As such: We are suspending new event postings in our newsletters and on Twitter. Visit our events page to see a complete list of events in the community.
| |
JOB OPPORTUNITIESNEW Research Technician – Hematopoietic Stem Cells (Karolinska Institutet) Postdoctoral Positions – Leukemia (Temple University School of Medicine) Postdoctoral Position – Hematopoietic Stem Cells (Lund University) Postdoctoral Researcher – Hematologic Malignancies (Northwestern University) Postdoctoral Position – Hematopoietic Stem Cell Biology (Columbia University Medical Center) Postdoctoral Positions – Cancer Research (Moores Cancer Center, UC San Diego) Team Leader – Clonal Evolution in Leukemias (Institute of Cancer Research) Postdoctoral Researcher – Leukemia (Universitätsklinikum Carl Gustav Carus Dresden) Postdoctoral Scientist – Stem Cell Biology (Cancer Research UK Manchester Institute) Laboratory Director – Cord Blood Processing (PerkinElmer) Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
| |
Have we missed an important article or publication in Cord Blood News? Click here to submit! Comments or suggestions? Submit your feedback here. | |
|